There is an error in the footnote of [Table 1](#pone.0231075.t001){ref-type="table"}. "Increase from baseline to end of Phase 1 within group, p \< 0.03" should be corrected to "Increase from baseline to end of Phase 1 within group, p\<0.05". Please see the correct [Table 1](#pone.0231075.t001){ref-type="table"} here.
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###### Clinical and physiological characteristics at baseline, changes at the end of Phase 1, and exercise performance in Phase 1.

![](pone.0231075.t001){#pone.0231075.t001g}

                                                                  Standard Group   Incentive Group                                                 
  --------------------------------------------------------------- ---------------- ----------------------------------------------- --------------- -----------------------------------------------
  BMI, kg/m^2^[\*](#t001fn003){ref-type="table-fn"}               34.9 ± 8.5       0.7 ± 1.1[†](#t001fn004){ref-type="table-fn"}   34.7 ± 6.2      0.7 ± 1.8[†](#t001fn004){ref-type="table-fn"}
  BMI, percentile                                                 98 ± 3           0 ± 1                                           98 ± 3          0 ± 1
  Body fat, %                                                     43.6 ± 8.1       0.9 ± 2.7                                       43.1 ± 6.9      0.1 ± 4.2
  Fat-free mass, kg                                               48.6 ± 10.2      0.6 ± 2.9                                       52.2 ± 10.2     0.9 ± 4.3
  Waist circumference, cm                                         104 ± 16         -1 ± 5                                          108 ± 12        0 ± 8
  VO~2~peak, ml/kg FFM/min[\*](#t001fn003){ref-type="table-fn"}   34.2 ± 7.1       3.4 ± 5.7[†](#t001fn004){ref-type="table-fn"}   35.2 ± 8.7      3.7 ± 7.5[†](#t001fn004){ref-type="table-fn"}
  Steps per day                                                   6,404 ± 3,425    -869 ± 2,318                                    6,218 ± 2,419   483 ± 3,401
  Glucose, mmol/l                                                 5.3 ± 0.5        0.2 ± 1.0                                       5.1 ± 0.4       0.4 ± 2.1
  Insulin, pmol/l                                                 164.7 ± 229.3    -2.9 ± 166.9                                    119.7 ± 94.3    -11.4 ± 80.3
  iHOMA2 (%S)                                                     74.9 ± 48.5      -13.8 ± 40.7                                    68.6 ± 44.2     -4.9 ± 26.2
  HbA1c (%)                                                       5.4 ± 0.3        0.1 ± 0.2[†](#t001fn004){ref-type="table-fn"}   5.3 ± 0.2       0.1 ± 0.6
  Exercise sessions performed                                     ---              26 ± 16                                         ---             28 ± 15
  Total MVPA time, h                                              ---              15.2 ± 10.1                                     ---             15.0 ± 8.1
  MVPA time per exercise session, minutes                         ---              35 ± 7                                          ---             32 ± 8
  MVPA time in moderate intensity range, %                        ---              63 ± 18                                         ---             64 ± 18
  Payments for exercise, USD\$                                    ---              99 ± 58                                         ---             245 ± 144[§](#t001fn005){ref-type="table-fn"}

Values shown as mean ± SD. BMI, body mass index; VO~**2**~peak, peak oxygen uptake during aerobic fitness test; FFM, fat-free mass; iHOMA2, integrated homeostatic model of assessment; HbA1c, hemoglobin A1c; MVPA, moderate-to-vigorous activity. The Standard group had 18 girls, 17 boys; mean age 14.2 ± 2.4 years at baseline.

The Incentive group had 25 girls, 17 boys; mean age 14.4 ± 2.3 years at baseline.

\* Main effect of time for entire cohort, p \< 0.01.

† Increase from baseline to end of Phase 1 within group, p \< 0.05.

§ Difference between groups, p \< 0.01.
